Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Rowling, Emily J"'
Autor:
Kadirvel, Manikandan, Fairclough, Michael, Cawthorne, Christopher, Rowling, Emily J., Babur, Muhammad, McMahon, Adam, Birkket, Paul, Smigova, Alison, Freeman, Sally, Williams, Kaye J., Brown, Gavin
Publikováno v:
In Bioorganic & Medicinal Chemistry 1 January 2014 22(1):341-349
Autor:
Rowling, Emily J.1 (AUTHOR), Miskolczi, Zsofia1 (AUTHOR), Nagaraju, Raghavendar1 (AUTHOR), Wilcock, Daniel J.1 (AUTHOR), Wang, Ping2 (AUTHOR), Telfer, Brian3 (AUTHOR), Li, Yaoyong4 (AUTHOR), Lasheras-Otero, Irene5 (AUTHOR), Redondo-Muñoz, Marta5 (AUTHOR), Sharrocks, Andrew D.4 (AUTHOR), Arozarena, Imanol5 (AUTHOR), Wellbrock, Claudia1 (AUTHOR) claudia.wellbrock@manchester.ac.uk
Publikováno v:
Pigment Cell & Melanoma Research. Sep2020, Vol. 33 Issue 5, p695-708. 14p.
Autor:
Smith, Michael P, Brunton, Holly, Rowling, Emily J, Ferguson, Jennifer, Arozarena, Imanol, Miskolczi, Zsofia, Lee, Jessica L, Girotti, Maria R, Marais, Richard, Levesque, Mitchell P, Dummer, Reinhard, Frederick, Dennie T, Flaherty, Keith T, Cooper, Zachary A, Wargo, Jennifer A, Wellbrock, Claudia
Publikováno v:
Smith, M, Brunton, H, Rowling, E, Ferguson, J, Arozarena, I, Miskolczi, Z, Lee, J L, Girotti, M, Marais, R, Levesque, M P, Dummer, R, Frederick, D T, Flaherty, K T, Cooper, Z A, Wargo, J A & Wellbrock, C 2016, ' Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. ', Cancer Cell, vol. 29, no. 3, pp. 270-284 . https://doi.org/10.1016/j.ccell.2016.02.003
Cancer Cell
Cancer Cell
Summary Once melanomas have progressed with acquired resistance to mitogen-activated protein kinase (MAPK)-targeted therapy, mutational heterogeneity presents a major challenge. We therefore examined the therapy phase before acquired resistance had d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::78ecb6f85c9c618f752bf8a3c798d70e
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Smith, Michael P, Rowling, Emily J, Miskolczi, Zsofia, Ferguson, Jennifer, Spoerri, Loredana, Haass, Nikolas K, Sloss, Olivia, McEntegart, Sophie, Arozarena, Imanol, von Kriegsheim, Alex, Rodriguez, Javier, Brunton, Holly, Kmarashev, Jivko, Levesque, Mitchell P, Dummer, Reinhard, Frederick, Dennie T, Andrews, Miles C, Cooper, Zachary A, Flaherty, Keith T, Wargo, Jennifer A, Wellbrock, Claudia
Publikováno v:
Smith, M, Rowling, E, Miskolczi, Z, Ferguson, J, Spoerri, L, Haass, N K, Sloss, O, McEntegart, S, Arozarena, I, Kriegsheim, A V, Rodriguez, J, Brunton, H, Kmarashev, J, Levesque, M P, Dummer, R, Frederick, D T, Flaherty, K T, Andrews, M, Cooper, Z A, Wargo, J A & Wellbrock, C 2017, ' Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure ', EMBO Molecular Medicine . https://doi.org/10.15252/emmm.201607156
EMBO Molecular Medicine
Smith, M P, Rowling, E J, Miskolczi, Z, Ferguson, J, Spoerri, L, Haass, N K, Sloss, O, McEntegart, S, Arozarena, I, von Kriegsheim, A, Rodriguez, J, Brunton, H, Kmarashev, J, Levesque, M P, Dummer, R, Frederick, D T, Andrews, M C, Cooper, Z A, Flaherty, K T, Wargo, J A & Wellbrock, C 2017, ' Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure ', EMBO Molecular Medicine . https://doi.org/10.15252/emmm.201607156
EMBO Molecular Medicine
Smith, M P, Rowling, E J, Miskolczi, Z, Ferguson, J, Spoerri, L, Haass, N K, Sloss, O, McEntegart, S, Arozarena, I, von Kriegsheim, A, Rodriguez, J, Brunton, H, Kmarashev, J, Levesque, M P, Dummer, R, Frederick, D T, Andrews, M C, Cooper, Z A, Flaherty, K T, Wargo, J A & Wellbrock, C 2017, ' Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure ', EMBO Molecular Medicine . https://doi.org/10.15252/emmm.201607156
Approaches to prolong responses to BRAF targeting drugs in melanoma patients are challenged by phenotype heterogeneity. Melanomas of a "MITF-high" phenotype usually respond well to BRAF inhibitor therapy, but these melanomas also contain subpopulatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::8cdcf444aebcef9c5474956100dbcf15
https://doi.org/10.15252/emmm.201607156
https://doi.org/10.15252/emmm.201607156
Autor:
Young, Helen L., Rowling, Emily J., Bugatti, Mattia, Giurisato, Emanuele, Luheshi, Nadia, Arozarena, Imanol, Acosta, Juan-Carlos, Kamarashev, Jivko, Frederick, Dennie T., Cooper, Zachary A., Reuben, Alexandre, Gil, Jesus, Flaherty, Keith T., Wargo, Jennifer A., Vermi, William, Smith, Michael P., Wellbrock, Claudia, Hurlstone, Adam
Publikováno v:
The Journal of Experimental Medicine
Young, H, Rowling, E, Bugatti, M, Giurisato, E, Luheshi, N, Arozarena, I, Acosta, J-C, Kamarashev, J, Frederick, D T, Cooper, Z A, Reuben, A, Gil, J, Flaherty, K T, Wargo, J A, Vermi, W, Smith, M, Wellbrock, C & Hurlstone, A 2017, ' An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition ', Journal of Experimental Medicine, vol. 214, no. 5 . https://doi.org/10.1084/jem.20160855
Young, H L, Rowling, E J, Bugatti, M, Giurisato, E, Luheshi, N, Arozarena, I, Acosta, J-C, Kamarashev, J, Frederick, D T, Cooper, Z A, Reuben, A, Gil, J, Flaherty, K T, Wargo, J A, Vermi, W, Smith, M P, Wellbrock, C & Hurlstone, A 2017, ' An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition ', Journal of Experimental Medicine, vol. 214, no. 6, pp. 1691–1710 . https://doi.org/10.1084/jem.20160855
Young, H, Rowling, E, Bugatti, M, Giurisato, E, Luheshi, N, Arozarena, I, Acosta, J-C, Kamarashev, J, Frederick, D T, Cooper, Z A, Reuben, A, Gil, J, Flaherty, K T, Wargo, J A, Vermi, W, Smith, M, Wellbrock, C & Hurlstone, A 2017, ' An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition ', Journal of Experimental Medicine, vol. 214, no. 5 . https://doi.org/10.1084/jem.20160855
Young, H L, Rowling, E J, Bugatti, M, Giurisato, E, Luheshi, N, Arozarena, I, Acosta, J-C, Kamarashev, J, Frederick, D T, Cooper, Z A, Reuben, A, Gil, J, Flaherty, K T, Wargo, J A, Vermi, W, Smith, M P, Wellbrock, C & Hurlstone, A 2017, ' An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition ', Journal of Experimental Medicine, vol. 214, no. 6, pp. 1691–1710 . https://doi.org/10.1084/jem.20160855
Drug tolerance brought about by reversible adaptive responses precedes the emergence of irreversible mutation-driven drug resistance and sustains tumor cells when at their most vulnerable. Young et al. delineate a signaling relay incorporating IL-1 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d689dd9b848bbf1ca933f242401a0bf2
http://hdl.handle.net/11379/493847
http://hdl.handle.net/11379/493847
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Burrows, Natalie, Williams, Joseph, Telfer, Brian A, Resch, Julia, Valentine, Helen R, Fitzmaurice, Richard J, Eustace, Amanda, Irlam, Joely, Rowling, Emily J, Hoang-Vu, Cuong, West, Catharine M, Brabant, Georg, Williams, Kaye J
Publikováno v:
Oncotarget
Burrows, N, Williams, J, Telfer, B, Resch, J, Valentine, H, Fitzmaurice, R, Eustace, A, Irlam, J, Rowling, E, Hoang-Vu, C, West, C, Brabant, G & Williams, K 2016, ' Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas ', Oncotarget, vol. 7, no. 39, pp. 63106-63123 . https://doi.org/10.18632/oncotarget.11056
Burrows, N, Williams, J, Telfer, B, Resch, J, Valentine, H, Fitzmaurice, R, Eustace, A, Irlam, J, Rowling, E, Hoang-Vu, C, West, C, Brabant, G & Williams, K 2016, ' Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas ', Oncotarget, vol. 7, no. 39, pp. 63106-63123 . https://doi.org/10.18632/oncotarget.11056
Anaplastic (ATC) and certain follicular thyroid-carcinomas (FTCs) are radioresistant. The Phosphatidylinositide 3-kinase (PI3K) pathway is commonly hyperactivated in thyroid-carcinomas. PI3K can modify the PI3K-related kinases (PIKKs) in response to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e1cabff1e987a84a7d9c621a2069a7a
https://www.repository.cam.ac.uk/handle/1810/323031
https://www.repository.cam.ac.uk/handle/1810/323031
Autor:
Smith, Michael P., Rana, Sareena, Ferguson, Jennifer, Rowling, Emily J., Flaherty, Keith T., Wargo, Jennifer A., Marais, Richard, Wellbrock, Claudia
Publikováno v:
Pigment Cell & Melanoma Research; Mar2019, Vol. 32 Issue 2, p280-291, 12p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.